Objective To explore the ‘real world’ effectiveness of tacrolimus therapy for refractory ulcerative proctocolitis (UC).
Design Retrospective cohort study using prospectively collated clinical data.
Setting A single district general hospital in Kent, UK. Clinical decisions and regular monitoring were undertaken by a single expert in inflammatory bowel disease.
Patients All patients started on tacrolimus between January 2010 and August 2016 at Tunbridge Wells Hospital.
Interventions Following failure of conventional medication, tacrolimus was commenced at 0.5 mg/kg twice daily. Drug trough levels of 5–20 ng/mL were targeted. Other immunomodulation was stopped and steroids were weaned over 4–6 weeks.
Main outcome measures Treatment duration was measured for each patient. If the drug was stopped, the rationale, including specific side effects, was recorded. The patient’s subsequent management plan was noted.
Results Thirty-five patients were started on tacrolimus (range: 18–85, median: 36 years). Disease extent included proctitis to pancolitis. Twenty-five patients derived no benefit. Four patients responded, but drug side effects necessitated withdrawal. Eighteen of these 29 patients (62%) underwent surgery. One patient, who had previously responded, stopped the drug after becoming pregnant (healthy subsequent birth). Therefore, 5 of 35 patients (14%) remain on tacrolimus with sustained clinical response, ranging from 6 to 76 (median: 32) months of treatment. Treatment was most effective for proctosigmoiditis. There were no other demographic or biological markers for success.
Conclusions In line with UK and European guidelines, tacrolimus can be beneficial for refractory UC. With appropriate monitoring, it appears treatment can be continued safely long term.
- inflammatory bowel syndrome
- ulcerative colitis
Statistics from Altmetric.com
Contributors AS performed retrospective data collection, data analysis and interpretation and wrote the manuscript. AH performed prospective data collection, advised about data analysis and interpretation and reviewed draft versions of the manuscript.
Competing interests None declared.
Ethics approval As this work is a prospective quality assurance audit, ethics committee approval is not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional unpublished data are available.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.